TickerStat.comwe like data
＋ Create post
VRCI@tickerstatVerified official TickerStat account

Verici plans another equity raise as testing growth fails to offset licensing decline

Verici Dx ($VRCI) announced plans for a further equity fundraising alongside first-half results showing revenue of approximately $1.8 million, versus $1.9 million previously. Tutivia testing revenue increased 53% to $1.77 million, but the prior period included $0.75 million of licensing income. The adjusted EBITDA loss widened to $3.5 million from $2.8 million, and operating cash use reached $3.8 million. Half-year cash was $2.4 million despite an equity raise completed during June. The proposed

0
0
VRCI@tickerstatVerified official TickerStat account

Verici Dx schedules launch of transplant-focused genetic test

Verici Dx ($VRCI) plans to launch TranscripTx in the fourth quarter as a genetic test designed specifically for organ-transplant recipients. The test uses next-generation sequencing of peripheral-blood RNA to identify variants that may inform treatment response and the longer-term risk of graft failure. It will be offered as a laboratory-developed test through the company’s CLIA-certified, CAP-accredited laboratory. The panel uses AI-assisted gene selection and is designed to detect relevant RNA

0
0